DNLI
Price
$15.11
Change
+$0.24 (+1.61%)
Updated
Apr 24, 02:34 PM (EDT)
Capitalization
2.12B
19 days until earnings call
MEIP
Price
$1.98
Change
-$0.00 (-0.00%)
Updated
Apr 24, 10:30 AM (EDT)
Capitalization
13.19M
Ad is loading...

DNLI vs MEIP

Header iconDNLI vs MEIP Comparison
Open Charts DNLI vs MEIPBanner chart's image
Denali Therapeutics
Price$15.11
Change+$0.24 (+1.61%)
Volume$100
Capitalization2.12B
MEI Pharma
Price$1.98
Change-$0.00 (-0.00%)
VolumeN/A
Capitalization13.19M
DNLI vs MEIP Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. MEIP commentary
Apr 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and MEIP is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 24, 2025
Stock price -- (DNLI: $14.87 vs. MEIP: $1.98)
Brand notoriety: DNLI and MEIP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 102% vs. MEIP: 32%
Market capitalization -- DNLI: $2.12B vs. MEIP: $13.19M
DNLI [@Biotechnology] is valued at $2.12B. MEIP’s [@Biotechnology] market capitalization is $13.19M. The market cap for tickers in the [@Biotechnology] industry ranges from $266.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileMEIP’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • MEIP’s FA Score: 0 green, 5 red.
According to our system of comparison, both DNLI and MEIP are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while MEIP’s TA Score has 5 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 4 bearish.
  • MEIP’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, MEIP is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +18.49% price change this week, while MEIP (@Biotechnology) price change was +1.54% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.07%. For the same industry, the average monthly price growth was -6.06%, and the average quarterly price growth was -12.59%.

Reported Earning Dates

DNLI is expected to report earnings on Jul 31, 2025.

MEIP is expected to report earnings on Aug 31, 2023.

Industries' Descriptions

@Biotechnology (+7.07% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.12B) has a higher market cap than MEIP($13.2M). MEIP YTD gains are higher at: -19.512 vs. DNLI (-27.036). MEIP has higher annual earnings (EBITDA): -29.13M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. MEIP (23.7M). MEIP has less debt than DNLI: MEIP (11.7M) vs DNLI (48.7M). DNLI (0) and MEIP (0) have equivalent revenues.
DNLIMEIPDNLI / MEIP
Capitalization2.12B13.2M16,068%
EBITDA-492.89M-29.13M1,692%
Gain YTD-27.036-19.512139%
P/E RatioN/A1.09-
Revenue00-
Total Cash832M23.7M3,511%
Total Debt48.7M11.7M416%
FUNDAMENTALS RATINGS
DNLI vs MEIP: Fundamental Ratings
DNLI
MEIP
OUTLOOK RATING
1..100
1579
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
3995
PRICE GROWTH RATING
1..100
6485
P/E GROWTH RATING
1..100
9836
SEASONALITY SCORE
1..100
5075

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MEIP's Valuation (60) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (94) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than DNLI’s over the last 12 months.

MEIP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as DNLI (100) in the Biotechnology industry. This means that MEIP’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (39) in the Biotechnology industry is somewhat better than the same rating for MEIP (95) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew somewhat faster than MEIP’s over the last 12 months.

DNLI's Price Growth Rating (64) in the Biotechnology industry is in the same range as MEIP (85) in the Pharmaceuticals Other industry. This means that DNLI’s stock grew similarly to MEIP’s over the last 12 months.

MEIP's P/E Growth Rating (36) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (98) in the Biotechnology industry. This means that MEIP’s stock grew somewhat faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIMEIP
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 10 days ago
72%
Declines
ODDS (%)
Bearish Trend 9 days ago
80%
Bearish Trend 14 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
79%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MEIP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JAVTX70.71N/A
N/A
Janus Henderson Venture T
MSGAX10.43N/A
N/A
Meridian Small Cap Growth A
MVSSX26.58N/A
N/A
Victory Integrity Small-Cap Value R6
FSGEX15.04N/A
N/A
Fidelity Series Global ex US Index
RKCIX9.47N/A
N/A
Rockefeller Climate Solutions Instl

MEIP and

Correlation & Price change

A.I.dvisor indicates that over the last year, MEIP has been loosely correlated with GOSS. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if MEIP jumps, then GOSS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MEIP
1D Price
Change %
MEIP100%
N/A
GOSS - MEIP
45%
Loosely correlated
+7.51%
DNLI - MEIP
30%
Poorly correlated
+1.85%
NRIX - MEIP
29%
Poorly correlated
+1.31%
FBIO - MEIP
28%
Poorly correlated
+3.27%
AXON - MEIP
28%
Poorly correlated
+3.82%
More